Market Currents
Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its...
-
Thursday, June 30, 2011, 11:56 AM ETCorcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively.
Other date
Latest Articles
